GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Liver diseases are any diseases that affect the functioning of the liver. Liver diseases can be inherited (such as Wilson disease and alpha 1-antitrypsin deficiency) or acquired (for example ...

Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

Denmark: Following a recent World Health Organization (WHO) alert on semaglutide-containing medicines, Novo Nordisk has ...

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

Unlike semaglutide, ecnoglutide preferentially targets the production ... such as sleep apnoea, fatty liver disease, chronic kidney disease and heart disease, he adds. “It’ll give us options and it ...

Both Wegovy and Ozempic are semaglutide – a drug that first entered the US market in 2017 as a diabetes medication. It was ...

Tweaking your daily routine so you move more, drink enough water, and sleep better are all helpful adjustments for anyone ...